P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY

P1588: LONG-TERM REAL-WORLD EFFECTIVENESS OF ELIGLUSTAT IN TREATMENT-NAÏVE AND SWITCH PATIENTS ENROLLED IN THE INTERNATIONAL COLLABORATIVE GAUCHER GROUP (ICGG) GAUCHER REGISTRY

Bibliographic Details
Main Authors:	Pramod Mistry, Manisha Balwani, Joel Charrow, Jeremy Lorber, Claus Niederau, Jenny Carwile, Sefika Uslu, Priya S. Kishnani
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000973228.21913.33

Similar Items

The Two Substrate Reduction Therapies for Type 1 Gaucher Disease Are Not Equivalent. Comment on Hughes et al. Switching between Enzyme Replacement Therapies and Substrate Reduction Therapies in Patients with Gaucher Disease: Data from the Gaucher Outcome Survey (GOS). <i>J. Clin. Med.</i> 2022, <i>11</i>, 5158
by: Pramod K. Mistry, et al.
Published: (2023-05-01)

Profile of eliglustat tartrate in the management of Gaucher disease
by: Sechi A, et al.
Published: (2016-01-01)

Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
by: Sechi A, et al.
Published: (2016-07-01)

Eliglustat tartrate for the treatment of adults with type 1 Gaucher disease
by: Bennett LL, et al.
Published: (2015-08-01)

Incremental biomarker and clinical outcomes after switch from enzyme therapy to eliglustat substrate reduction therapy in Gaucher disease
by: Nathaniel Kleytman, et al.
Published: (2021-12-01)

A Japanese Patient with Gaucher Disease Treated with the Oral Drug Eliglustat as Substrate Reducing Therapy
by: Naoto Komada, et al.
Published: (2021-09-01)

The role of glucosylsphingosine as an early indicator of disease progression in early symptomatic type 1 Gaucher disease
by: Ashlee R. Stiles, et al.
Published: (2021-06-01)

Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
by: Majdolen Istaiti, et al.
Published: (2022-10-01)

Safety and efficacy of eliglustat combined to enzyme replacement therapy for lymphadenopathy in patients with Gaucher disease type 3
by: Ni-Chung Lee, et al.
Published: (2022-06-01)

Real life data: follow-up assessment on Spanish Gaucher disease patients treated with eliglustat. TRAZELGA project
by: Irene Serrano-Gonzalo, et al.
Published: (2023-12-01)

Effects of paroxetine, ketoconazole, and rifampin on the metabolism of eliglustat, an oral substrate reduction therapy for Gaucher disease type 1
by: Lucie Vu, et al.
Published: (2020-03-01)

Gaucher Disease and Gaucher Cells
by: Sevgi Gözdaşoğlu
Published: (2015-05-01)

Characteristics of 26 patients with type 3 Gaucher disease: A descriptive analysis from the Gaucher Outcome Survey
by: Ida Vanessa D. Schwartz, et al.
Published: (2018-03-01)

Long-term adverse event profile from four completed trials of oral eliglustat in adults with Gaucher disease type 1
by: M. Judith Peterschmitt, et al.
Published: (2019-06-01)

Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat
by: Karamjot Sidhu, et al.
Published: (2020-09-01)

Case report of unexpected gastrointestinal involvement in type 1 Gaucher disease: comparison of eliglustat tartrate treatment and enzyme replacement therapy
by: Yoo-Mi Kim, et al.
Published: (2017-05-01)

Gaucher Cells or Pseudo-Gaucher Cells: That's the Question
by: Deniz Gören Şahin, et al.
Published: (2014-12-01)

P1541: PRELIMINARY RESULTS OF TWO YEARS FOLLOW-UP OF TYPE 1 GAUCHER DISEASE PATIENTS TREATED WITH ELIGLUSTAT IN TRAZELGA PROJECT.
by: I. Serrano-Gonzalo, et al.
Published: (2022-06-01)

Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism
by: Makaila L. Furderer, et al.
Published: (2022-05-01)

Gaucher disease.
by: Butters, T
Published: (2007)

Gaucher Disease
by: Guilherme Henrique Hencklain Fonseca, et al.
Published: (2007-03-01)

Gaucher′s disease
by: Vijay Bohra, et al.
Published: (2011-01-01)

Women with Gaucher Disease
by: Maria del Mar Meijon-Ortigueira, et al.
Published: (2024-03-01)

Gaucher Disease for Hematologists
by: Gül Nihal Özdemir, et al.
Published: (2022-05-01)

Enfermedad de gaucher
by: Magaly Mendoza-Quispe
Published: (2018-04-01)

Doença de Gaucher.
by: L P Trindade e Silva, et al.
Published: (2007-04-01)

PB2551: GAUCHER DISEASE CURRICULUM: INCORPORATING GAUCHER DISEASE IN THE FIELD OF HEMATOLOGY
by: Argiris Symeonidis, et al.
Published: (2023-08-01)

Reversal of life-threatening hepatopulmonary syndrome in Gaucher disease by imiglucerase enzyme replacement therapy
by: Amal El Beshlawy, et al.
Published: (2019-09-01)

Gaucher's disease management protocol
by: E. A. Lukina, et al.
Published: (2022-11-01)

Lung Involvement in Gaucher Disease
by: Mahnaz Pejman Sani, et al.
Published: (2020-04-01)

Enzyme replacement in Gaucher disease.
by: Ernest Beutler
Published: (2004-11-01)

Prevalence and management of Gaucher disease
by: Burrow TA, et al.
Published: (2011-06-01)

Management algorithms for gaucher disease
by: Ayman Alhejazi, et al.
Published: (2020-01-01)

Hemorrhagic Aspects of Gaucher Disease
by: Hanna Rsenbaum
Published: (2014-10-01)

Splenic lipids in Gaucher's disease
by: N.G. Kennaway, et al.
Published: (1968-11-01)

Exodontia in patient with Gaucher's disease
by: Guacyra Machado Lisboa, et al.
Published: (2011-12-01)

The structure of cerebrosides in Gaucher's disease*
by: G.V. Marinetti, et al.
Published: (1960-04-01)

Estudo da doença de Gaucher em Santa Catarina Study of Gaucher disease in Santa Catarina
by: Jovino S. Ferreira, et al.
Published: (2008-02-01)

Treatment of profound thrombocytopenia in a patient with Gaucher disease type 1: Is there a role for substrate reduction therapy
by: Christine I. Ha, et al.
Published: (2017-09-01)

Corticobasal syndrome in a man with Gaucher disease type 1: Expansion of the understanding of the neurological spectrum
by: Kunal C. Potnis, et al.
Published: (2018-12-01)